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Electrophysiologic Mechanism Underlying Action Potential
Prolongation by Sevoflurane in Rat Ventricular Myocytes
Jee Eun Chae, M.S.,* Duck Sun Ahn, M.D., Ph.D.,† Myung Hee Kim, M.S.,‡ Carl Lynch III, M.D., Ph.D.,§
Wyun Kon Park, M.D.
Background: Despite prolongation of the QTc interval in hu-
mans during sevoflurane anesthesia, little is known about the
mechanisms that underlie these actions. In rat ventricular myo-
cytes, the effect of sevoflurane on action potential duration and
underlying electrophysiologic mechanisms were investigated.
Methods: The action potential was measured by using a cur-
rent clamp technique. The transient outward K current was
recorded during depolarizing steps from 80 mV, followed by
brief depolarization to 40 mV and then depolarization up to
60 mV. The voltage dependence of steady state inactivation
was determined by using a standard double-pulse protocol. The
sustained outward current was obtained by addition of 5 mM
4-aminopyridine. The inward rectifier K current was recorded
from a holding potential of 40 mV before their membrane
potential was changed from 130 to 0 mV. Sevoflurane actions
on L-type Ca2 current were also obtained.
Results: Sevoflurane prolonged action potential duration,
whereas the amplitude and resting membrane potential re-
mained unchanged. The peak transient outward K current at
60 mV was reduced by 18  2% (P < 0.05) and 24  2% (P <
0.05) by 0.35 and 0.7 mM sevoflurane, respectively. Sevoflurane
had no effect on the sustained outward current. Whereas 0.7 mM
sevoflurane did not shift the steady state inactivation curve, it
accelerated the current inactivation (P < 0.05). The inward
rectifier K current at 130 mV was little altered by 0.7 mM
sevoflurane. L-type Ca2 current was reduced by 28  3% (P <
0.05) and 33  1% (P < 0.05) by 0.35 and 0.7 mM sevoflurane,
respectively.
Conclusions: Action potential prolongation by clinically rele-
vant concentrations of sevoflurane is due to the suppression of
transient outward K current in rat ventricular myocytes.
SEVOFLURANE has been reported to prolong QTc inter-
val in healthy adults1,2 and children3,4 during anesthesia
induction. Furthermore, sevoflurane has been reported
to markedly prolong the QT intervals in children with
congenital long QT syndrome.5,6 In in vitro animal prep-
arations using guinea pig ventricular myocardium7 and
myocytes,8,9 sevoflurane prolonged the action potential
(AP) duration. This seemed to be caused by inhibition of
the slowly activating delayed outward K current with
minimal effect on the inward rectifier K current (IKI).
In contrast to this prolonging effect, shortening of AP
duration by sevoflurane has also been observed in guinea
pig myocardium,10 canine,11 and rat ventricular myo-
cytes.12
Cardiac AP duration is determined by a balance be-
tween inward and outward membrane currents.13,14 In
most species, the transient outward K current (Ito) is
responsible for the initial phase of repolarization, and
the L-type Ca2 current (ICa, L) is the main inward cur-
rent during the plateau phase. The delayed outward K
current (IK) activation initiates repolarization near the
end of the ventricular AP plateau, and the IKI plays an
important role in generating the resting membrane po-
tential and in modulating the final repolarization phase
of the ventricular AP.14 The contribution of these cur-
rents varies between species and is responsible for the
characteristic differences in AP shapes. For example, rat
ventricular myocytes possess a prominent Ito, the major
outward current of the repolarization phase, but little IK,
and have a short AP duration. In contrast, guinea pig
ventricular cells lack Ito, but have a slowly activating Ik,
resulting in a long-lasting AP.15
In rat ventricular myocytes, Rithalia et al.12 observed a
shortening effect of sevoflurane on AP duration, attrib-
uted to the reduced ICa, L, with little effect on Ito. In
another recent study9 using cloned human cardiac K
channels, sevoflurane inhibited Kv4.3 cardiac K chan-
nel currents, suggesting inhibition of Ito. Based on the
similar electrophysiologic characteristics of Ito between
human and rat ventricular myocytes,16 we speculated
that the Ito in rat heart cells may be inhibited by sevoflu-
rane. During preliminary experiments, we observed con-
centration-dependent prolongation of AP duration in rat
ventricular myocytes, which contradicted the results of
Rithalia et al.12 Therefore, to elucidate the mechanisms
of AP prolongation, we examined the effect of sevoflu-
rane on Ito and inward rectifier K
 current (IKI), as well
as ICa, L.
Materials and Methods
Myocyte Isolation
According to a protocol approved by the Yonsei
University College of Medicine Animal Research Com-
mittee (Seoul, Korea), the heart was quickly excised
from rats (Sprague-Dawley, weighing 250 –300 g) after
halothane anesthesia. The excised heart was retro-
gradely perfused by using a Langendorff perfusion
system for 5 min at 37°C. The perfusion was at a rate
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of 7 ml/min with modified Tyrode solution containing
143 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 0.5 mM
MgCl2, 5 mM HEPES, and 0.18 mM glucose, pH 7.4. The
perfusate was then switched to a nominally Ca2-free
Tyrode solution for 5 min, followed by perfusion with
the same solution to which collagenase (0.4 mg/ml,
Worthington type II; Worthington Biochemical Corpo-
ration, Lakewood, NJ) and hyaluronidase (0.4 mg/ml,
Sigma type II; Sigma-Aldrich Co., St. Louis, MO) had
been added. After 10 –12 min of enzymatic treatment,
a final perfusion was performed for 5 min with a
Kraftbru¨he solution (10 mM taurine, 10 mM oxalic acid,
70 mM glutamic acid, 35 mM KCl, 10 mM H2PO4, 11 mM
glucose, 0.5 mM EGTA, and 10 mM HEPES, pH 7.4). The
ventricles were then cut off, minced with scissors, and
agitated in a small beaker of a Kraftbru¨he solution. The
resulting slurry was filtered through a 200-m nylon
mesh. The isolated ventricular cells were stored in a
Kraftbru¨he solution for 1 h at room temperature (21°–
22°C), then kept at 4°C, and used within a period of
8 h. Only the rod-shaped cells with apparent striations
that remained quiescent in the solution containing 2
mM CaCl2 were used for the experiments. All experi-
ments were performed at room temperature.
Electrophysiologic Techniques
Isolated myocytes were allowed to settle to the bottom
of a recording chamber, which was mounted onto an
inverted microscope where the bathing solutions could
be exchanged. The chamber was continuously perfused
at a constant rate (2 ml/min). Standard whole cell voltage
clamp methods were used.17 To establish a stable base-
line, an interval of 4–6 min was allowed after initiating
the whole cell recording configuration. Voltage clamp
measurements were performed by using an Axopatch
200B patch clamp amplifier (Axon Instruments Inc., Fos-
ter City, CA). Patch electrodes were prepared from a
borosilicate glass model KIMAX-51 (American Scientific,
Charlotte, NC), which have a typically 2- to 3-M resis-
tance when filled with an internal solution. After fabri-
cating the pipettes with a two-stage micropipette puller,
the pipette tips were heat-polished by using a micro-
forge. Data acquisition was performed by using a
pCLAMP system version 6.0 (Axon Instruments Inc.)
coupled with a Pentium-III personal computer.
Voltage Clamp Protocols
The APS were elicited in current-clamp mode by 5-ms,
800-pA current injections at a frequency of 1 Hz.
To examine Ito, from a holding potential of 80 mV,
the cells were depolarized to 40 mV for 50 ms to
inactivate the Na current and then depolarized to test
potentials of up to60 mV in 10-mV increments for 300
ms. To obtain more information about the possible
mechanism of sevoflurane-induced voltage blockade of
K currents, the voltage dependence of steady state
inactivation was determined by using a standard double-
pulse protocol. The membrane potential was initially
clamped at 80 mV and then stepped to different po-
tentials ranging from100 to 0 mV in 10-mV increments
for 500 ms followed by a 200-ms test pulse to 80 mV.
The voltage clamp protocol was repeated every 2 s. The
steady state inactivation data were fitted by a Boltzmann
distribution of the following equation: I/Imax  I/{1 
exp [(V  V1/2)]/}, where Imax is the maximal current,
V1/2 is the membrane potential producing 50% inactiva-
tion, and  is the slope factor.
To test whether the accelerated inactivation of Ito in
the presence of sevoflurane was associated with time-
dependent block of the open channel, the magnitude of
current inhibition at various times after the initiation of
the depolarizing pulse was determined at the membrane
potential of60 mV. The outward current in the presence
of each concentration of sevoflurane, expressed as a pro-
portion of the outward current observed in the control,
was plotted as a function of time after the start of depolar-
ization. A hyperbola function [y  Bmax (x/(kd  x))] was
used to fit the rate of block of Ito at each concentration of
sevoflurane. Bmax is the maximum block at drug concen-
tration; Kd is the dissociation constant.
The sustained outward current (Isus) was recorded
with the same voltage protocol after addition of 5 mM
4-aminopyridine, which preferentially blocks Ito, in mod-
ified Tyrode solution. The outward currents activated by
depolarizing voltage steps in rat ventricular myocytes
consist of a rapidly inactivating component, Ito, and a
noninactivating, sustained component, Isus.
18,19 The sus-
tained outward currents, comprising IK and a small time-
independent outward current,18 remain in the presence
of 4-aminopyridine. Whereas Ito underlies the initial,
rapid repolarization phase of the AP, Isus is responsible
for the slower phase of AP repolarization back to the
resting membrane potential in adult rat ventricular myo-
cytes.20
The effect on the IKI was verified by measuring the IKI
by step depolarizations from 130 to 0 mV from a
holding potential of40 mV in 10-mV increments, using
a 200-ms pulse applied at 5-s intervals.
The voltage-dependent ICa, L was evoked by step depo-
larizations that lasted 200 ms from a holding potential of
40 mV to10 mV in one step at a frequency of 0.1 Hz.
After the baseline measurements, myocytes were ex-
posed to 1.7% or 3.4% sevoflurane for 2–3 min, and
recovery responses were measured after washes for 2–3
min to remove the drugs. A 2-min application of sevoflu-
rane was sufficient to produce a stable and consistent
effect in pilot experiments.
Solutions and Chemicals
Before establishing the whole cell recording configu-
ration, modified Tyrode solution, containing 140 mM
NaCl, 5.4 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 5 mM HEPES,
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and 10 mM glucose, adjusted to pH 7.4 with 1N NaOH, was
used as an external bathing solution. For K current mea-
surements, a patch pipette solution was used, containing
20 mM KCl, 110 mM K-aspartate, 10 mM EGTA, 10 mM
HEPES, 1 mM MgCl2, 5 mM K2ATP, 1 mM CaCl2, and 10 mM
NaCl, adjusted to pH 7.2 with 3N KOH. To measure Isus, 5
mM 4-aminopyridine was added to the modified Tyrode
solution. As the pH of the modified Tyrode solution con-
taining 4-aminopyridine revealed 9.04  0.03 (n  2), the
pH was corrected to 7.4 with HCl before the experiment.
To eliminate any confounding Ca2 current, 0.2 mM CdCl2
was added to the external solution after establishing the
whole cell voltage clamp.
The inward Ca2 current was measured by using a patch
pipette solution containing 30 mM CsCl, 100 mM aspartic
acid, 100 mM CsOH, 10 mM BAPTA, 10 mM HEPES, 10 mM
phosphocreatine, 1 mM Na2GTP, 5 mM Na2ATP, 10 mM
glucose, and 2 mM MgCl2, adjusted to pH 7.2 with 1 M
CsOH. Once whole cell recording was achieved, the bath-
ing solution was exchanged to 140 mM NaCl, 5.4 mM CsCl,
2 mM CaCl2, 1 mM MgCl2, and 10 mM HEPES, adjusted to pH
7.4 with 1 M CsOH. Sevoflurane was purchased from the
Abbott Korea Ltd. (Seoul, Korea), and all other chemicals
were purchased from Sigma-Aldrich Co. (St. Louis, MO).
Before perfusion, sevoflurane was equilibrated in solu-
tion in one reservoir by passing 100% O2 (flow rate: 0.2
l/min) for 15 min through a sevoflurane vaporizer (Sevotec
3; Ohmeda, West Yorkshire, United Kingdom). The end-
tidal concentrations of sevoflurane were monitored by us-
ing a calibrated gas analyzer (Capnomac; Datex, Helsinki,
Finland). As determined by gas chromatographic measure-
ment, sevoflurane concentrations in the room-temperature
Tyrode superfusate equilibrated for 15 min were 0.35 mM
(n 4) and 0.7 mM (n 4) for 1.7% and 3.4% sevoflurane,
respectively. With the Tyrode solution/gas partition coeffi-
cient of sevoflurane of 0.40 at 22°C,21 0.35 and 0.7 mM
sevoflurane correspond to gas phase concentrations of
2.12% and 4.24%, respectively.
Statistical Analysis
Repeated measures of analysis of variance followed by
the Student-Newman-Keuls test were applied to test for
significant differences among control, drug application,
and washout. An unpaired t test was used to compare the
differences in currents of Ito, IKI, and ICa, L between 1.7%
and 3.4% sevoflurane. All values are expressed as mean 
SEM. A P value less than 0.05 was considered significant.
Results
Normal Action Potential
Figure 1 shows concentration-dependent prolongation
of AP duration observed in a rat ventricular myocyte.
Sevoflurane at 0.35 mM (n 6) prolonged the APD50 and
APD90 to 129 10% (P 0.05) and 115 2% (P 0.05)
of the control, respectively. Sevoflurane at 0.7 mM (n 
7) also prolonged the APD50 andAPD90 to 133 3% (P
0.05) and 139  6% (P  0.05) of the control, respec-
tively. The AP amplitude and resting membrane potential
remained unaltered at either concentration (table 1).
The AP duration was completely restored to baseline
after washout.
Transient Outward K Current
At a membrane potential of 60 mV, 0.35 mM sevoflu-
rane reduced the control peak currents of Ito (3.82  0.54
nA) by 18 2% (n 7; P 0.05), and the plateau currents
measured at the end of depolarization (1.51 0.12 nA) by
10  3% (n  7; P  0.05). Sevoflurane, 0.7 mM, reduced
peak currents of Ito (3.64 0.30 nA) by 24 2% (n 11;
P  0.05) and plateau currents (1.52  0.19 nA) by 10 
2% (n  11; P  0.05) (figs. 2A–C). Complete recovery of
peak and plateau currents was observed after washout of
either concentration (figs. 2A and B).
Under control conditions, the voltage required for half-
inactivation (V1/2) and slope factor () for the Ito were
31.53  0.68 mV and 6.23  0.60 mV, respectively
(n  7). Sevoflurane, 0.7 mM, did not shift the steady
Fig. 1. Effect of sevoflurane (SEVO) on action potential duration
in a rat ventricular myocyte. C  control.
Table 1. Effects of Sevoflurane on Action Potential
Characteristics in Isolated Rat Ventricular Myocytes
RMP, mV AMP, mV APD50, ms APD90, ms
0.35 mM SEVO (n  6)
Control 74  2 130  5 5.52  1 19.56  2
SEVO 74  3 127  6 6.87  1* 22.45  2*
Washout 74  3 128  6 6.27  1 20.24  2
0.7 mM SEVO (n  7)
Control 74  2 134  3 5.29  0 18.49  0
SEVO 74  2 128  4 7.01  1* 25.58  1*†
Washout 75  3 129  5 5.27  0 17.02  1
Values represent mean  SEM.
* P  0.05, different from control and washout values. † P  0.05, different
from 0.35 mM sevoflurane (SEVO).
AMP  action potential amplitude; APD50  action potential duration mea-
sured at 50% of repolarization; APD90  action potential duration measured
at 90% of repolarization; RMP  resting membrane potential.
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state inactivation curve (V1/2  35.04  0.84 mV,  
7.40  0.74, n  7; not significant) (fig. 3).
Because application of 0.7 mM sevoflurane in figure 2A
indicated that sevoflurane accelerated the decay of cur-
rent during the pulse, we evaluated the effect of sevoflu-
rane on the kinetics of inactivation of Ito. Individual
current records evoked by a test pulse to 60 mV were
fitted with a double exponential function. Figures 4A
and B show quality of fit of the double exponential
function to the inactivation phase of Ito under control
conditions and in the presence of 0.7 mM sevoflurane,
respectively. The control 1 (47  3 ms) was reduced to
27  3 ms by 0.7 mM sevoflurane (n  7; P  0.05).
Inactivation kinetics returned to baseline values after
washout (47  4 ms) (fig. 4C).
Figure 5 shows the inhibition of Ito by 0.35 and 0.7 mM
sevoflurane during depolarization. The inhibition in-
creased in a hyperbolic manner during depolarization.
Both the magnitude of the maximum inhibition and the
rate of development of the maximum inhibition seemed
to be concentration dependent. The Bmax values of 0.35
and 0.7 mM sevoflurane were 0.6 (n  7) and 0.82 (n 
8), respectively. The Kd values of 0.35 and 0.7 mM
sevoflurane were 19.66 ms (n 7) and 15.84 ms (n 8),
respectively.
Sustained Outward Current
Representative tracings of isolated Isus by application
of 5 mM 4-aminopyridine are illustrated in figures 6A and
B. Sevoflurane, 0.7 mM, had no effect on the Isus (n  6)
(fig. 6C). Before sevoflurane exposure, the baseline value
of Isus at the end of the plateau during test potential of
60 mV was 1.31  0.12 nA (n  6).
Inward Rectifier K Current
At membrane potential ranges from 130 to 0 mV, 0.7
mM sevoflurane did not alter the IKI (n 7; not significant)
(fig. 7B). The IKI was measured at the end of the pulse
duration. Before sevoflurane exposure, the baseline value
during test potential of 130 mV was 2.92  0.25 nA.
L-type Ca2 Current
At a membrane potential of 10 mV, 0.35 and 0.7 mM
sevoflurane reduced the ICa, L by 28  3% (n  8; P 
0.05) and 33  1% (n  7; P  0.05), respectively (fig.
8B). The effect of sevoflurane on ICa, L was completely
reversible after washout. The baseline values before ex-
posure to 0.35 and 0.7 mM sevoflurane were 0.75  0.09
and 0.81  0.2 nA, respectively.
Discussion
This study shows that clinically relevant concentra-
tions of sevoflurane prolong the AP duration and signif-
Fig. 2. Effects of sevoflurane (SEVO) on transient outward K
currents (Ito) in rat ventricular myocytes. (A) Recordings of
control, 0.7 mM SEVO, and recovery in a rat ventricular myo-
cyte. (B) Current–voltage relations of Ito. Closed and open cir-
cles indicate the peak current of Ito at every potential in the
control and in the presence of 0.7 mM SEVO. Squares are the
peak (closed) and plateau (open) currents after washout. Dotted
lines also indicate recovery. Triangles are the plateau current
levels at the end of the test pulses before (closed) and after
(open) application of 0.7 mM SEVO. (C) Effect of 0.35 and 0.7 mM
SEVO on the amplitude of peak Ito at 60 mV. * P < 0.05 versus
control. Error bars indicate mean  SEM.
Fig. 3. Steady state inactivation curves of transient outward K
currents under control conditions and in the presence of 0.7
mM sevoflurane (SEVO). Closed and open circles indicate con-
trol and 0.7 mM SEVO, respectively. Data are presented as mean
 SEM for four cells and were fitted with the Boltzmann func-
tion. The half-inactivations (V1/2) of control and 0.7 mM SEVO
were 31.53  0.68 and 35.04  0.84 mV, respectively, which
showed no differences. Error bars indicate mean  SEM.
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icantly inhibit the Ito and ICa, L in isolated rat ventricular
myocytes. Although sevoflurane did not shift the steady
state inactivation curve, it significantly accelerated inac-
tivation of Ito.
Prolongation of the ventricular AP duration by sevoflu-
rane has been observed in guinea pigs,7–9 whereas other
studies using canine ventricular cells11 or guinea pig
papillary muscles10 have reported shortening of the AP
duration. In a study using rat ventricular cells, sevoflu-
rane caused modest but significant shortening of AP
duration,12 a curious difference from our study despite
use of the same animal species.
In rat ventricular myocytes, cardiac voltage-activated K
current consists of Ito and IK, sensitive to 4-aminopyridine
and tetraethylammonium, respectively.20 In frog and
guinea pig ventricular myocytes, the dominant voltage-
activated outward K current is IK.
22,23 However, in rat,
dog, rabbit, and human myocytes, Ito is prominent and
plays a significant role in the early repolarization phase of
the AP.24–27 In several cardiac tissues, two types of Ito have been identified; one is voltage- and Ca2-independent, and
the other is Ca2-dependent.28,29 In rat ventricular myo-
cytes, only a Ca2-independent Ito has been identified.
30
The Ca2-independent Ito, carried predominantly by K

ions, has been suggested to be a major determinant of the
cardiac AP duration because of its large size and pro-
nounced frequency dependence.29
Rithalia et al.,12 in their study using rat ventricular
subendocardial and subepicardial myocytes, observed
no changes of Ito by application of 0.6 mM sevoflurane
Fig. 4. Effect of sevoflurane (SEVO) on current inactivation. The
inactivation phase of transient outward K currents (Ito) were
best fitted by a double exponential function under control con-
ditions (A) and in the presence of 0.7 mM SEVO (B) in a rat
ventricular myocyte. Mean values ( SEM) of 1 (n  7) under
control conditions, in the presence of 0.7 mM SEVO, and after
washout (C). * P< 0.05 versus control and recovery. Error bars
indicate mean  SEM.
Fig. 5. Time-dependent inhibition of transient outward K cur-
rents (Ito) by sevoflurane. Time course of the development of
the inhibition by 0.35 mM (n  7) and 0.7 mM (n  8) sevoflu-
rane after a depolarizing pulse to 60 mV from a holding
potential of 40 mV. The reduction of Ito in the presence of
sevoflurane is expressed as a proportion of the control current
at any given time after the start of the depolarizing pulse.
Fig. 6. Effect of sevoflurane (SEVO) on sustained outward cur-
rents (Isus) in a rat ventricular myocyte. (A) A control recording
of transient outward K currents (Ito). (B) Isus obtained after
application of 5 mM 4-aminopyridine (4-AP), which preferen-
tially blocks Ito. (C) 0.7 mM SEVO exposure after application of
5 mM 4-aminopyridine.
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(30°C). In contrast, we found that sevoflurane caused a
modest but significant depression of approximately 24%
by 0.7 mM sevoflurane (22°C). In a recent study using
cloned human cardiac K channels, 3 mM sevoflurane
inhibited the Kv4.3 cardiac K channel currents by ap-
proximately 28% (35°C), suggesting inhibition of Ito.
9
Kv4.3 channel has been reported to underlie a signifi-
cant fraction of Ito in the heart of several species, includ-
ing rat, canine, and human.31 Considering lower solubil-
ity at higher temperatures, the 0.6 mM sevoflurane at
30°C is estimated to be around 0.7 mM at 22°C.7 Despite
application of a similar concentration in the same animal
species, it remains unclear why a disparity exists be-
tween the result of Rithalia et al. and ours. In the above
study using cloned human cardiac K channels, 0.43 mM
sevoflurane at 37°C will be approximately 0.7 mM at
22°C.7 Although a 0.43 mM concentration of sevoflurane
caused modest depression of the Kv4.3 cardiac K chan-
nel currents, significant acceleration of the rate of decay
was shown at this concentration,9 indicating a possible
significant open channel inhibition in clinically relevant
concentrations of sevoflurane. Considering the similar
electrophysiologic characteristics of Ito between human
and rat ventricular myocytes,16 reduction of Ito in our
results seems to correspond to that of Kang et al.9 The
prolongation of AP duration as a result of inhibition of Ito
has been demonstrated with tedisamil, a blocker of Ito
and IK in isolated rat ventricular myocytes,
32 and was
similar to that reported in isolated rat papillary mus-
cles.33 Our findings of approximately 24% reduction of
Ito appear as a small fractional reduction. However, con-
sidering the large current density in rat ventricular myo-
cytes, 19.9  2.8 pA/pF at the membrane potential of
60 mV,16 the effect on the plateau phase will be
greater, resulting in AP prolongation.
The current study shows that sevoflurane decreased
the peak Ito and also accelerated the rate of decay. The
acceleration of the rate of decay could be explained by
an anesthetic-induced acceleration of the normal conver-
sion of open channels to an inactivated state with sus-
tained depolarization. Sevoflurane could preferentially
inhibit the open state of the channel. These findings are
similar to that previously reported in rat ventricular Ito
for quinidine (class Ia antiarrhythmic agent),34 clofi-
lium,35 tedisamil (class III antiarrhythmic agent),32 bu-
pivacaine,36 and imipramine in rabbit atrial Ito.
37
In the current study, whereas there was no inhibition
of Ito at the onset of the depolarizing pulses, we ob-
served the inhibition of Ito upon continued depolariza-
tion. These results may indicate that sevoflurane does
not bind to the resting state of the channel in an inhib-
itory fashion, but rather inhibits the open channel in a
hyperbolic manner during continued depolarization.
The lack of any effect on the voltage dependence of the
steady state inactivation suggests that sevoflurane does
not bind to the inactivated state of the channel.
The sustained outward currents, comprising IK and a
small time-independent outward current,18 remain in the
presence of 4-aminopyridine and tetraethylammonium.
Isus contributes to the overall repolarization process in
Fig. 7. Effect of sevoflurane (SEVO) on inward rectifier K cur-
rent (IKI) in rat ventricular myocytes. (A) Closed and open
circles indicate control and 0.7 mM SEVO in a rat ventricular
myocyte, respectively, at a membrane potential of130 mV. (B)
Current–voltage relations for IKI before and after addition of 0.7
mM SEVO (n  7). Closed and open circles indicate control and
0.7 mM SEVO, respectively. Error bars indicate mean  SEM.
Fig. 8. Effect of sevoflurane (SEVO) on L-type Ca2 current (ICa, L).
(A) A representative example of the effect of SEVO on ICa, L in a rat
ventricular myocyte. The open circles represent the peak of an
individual current record. The horizontal bar indicates the period
when SEVOwas applied. (Inset) An example of individual currents
recorded in the presence of 0.7 mM SEVO. (B) Depression of ICa, L
after application of 0.35 and 0.7 mM SEVO, respectively. * P< 0.05
versus control. Error bars indicate mean  SEM.
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rat ventricular myocytes. Whereas 0.7 mM sevoflurane
has been reported to significantly depress the IK in
guinea pig ventricular cells, approximately 60%,7 Isus
was not affected by sevoflurane. Although suppression
of IK by sevoflurane in guinea pig ventricular myocytes is
mainly responsible for the AP prolongation, Isus does not
likely contribute to the prolongation of AP duration by
sevoflurane in rat ventricular myocytes. Presumably, lit-
tle Isus change by sevoflurane may be attributed to
marked variations among cells in rat ventricle in the
relative amplitudes of Ito and IK (Ito/IK),
21 significant
inhibition of IK by 4-aminopyridine at concentrations
above 1 mM,18 and/or species differences.
The IKI is the primary current responsible for maintain-
ing a stable cardiac resting membrane potential near the
K equilibrium potential. Inhibition of IKI can result in
diastolic depolarization, which can increase cardiac ex-
citability38 and lead to dysrhythmias and abnormal auto-
maticity.39 Both sevoflurane and isoflurane have been
reported to cause significant depression of inward com-
ponent and enhancement of outward component of IKI
in guinea pig ventricular myocytes.40,41 However, the
actual differences from baseline values seemed to be
modest, suggesting minimal effect on IKI by these anes-
thetics. Modest effects on inward and outward compo-
nents of IKI by sevoflurane have been reported in guinea
pig ventricular myocytes,7 and our results in rat ventric-
ular myocytes also showed no depression of the inward
component of IKI by sevoflurane. The lack of change in
the resting membrane potential after application of 0.7
mM sevoflurane in our results may also reflect the lack of
effect on IKI.
In the current study on steady state inactivation of Ito,
approximately 80% of the channels seemed to be avail-
able for activation at 40 mV. This indicates that the
outward component of IKI above 40 mV may include
Ito and thus can influence the outward component of IKI
in this preparation.
Our whole cell voltage clamp studies revealed a reduc-
tion of peak ICa, L despite the prolongation of AP dura-
tion. Suppression of ICa, L by sevoflurane has been re-
ported in various animal preparations.7,9,11,12 Inhibition
of ICa, L can lead to a shortening of AP duration, however,
the reduction of Ito would seem to have a greater effect,
resulting in lengthening of the AP duration.
In human ventricular myocytes, although the current
density of Ito has been reported to be two or three times
smaller than that of the rat myocytes (8.2  0.7 pA/pF at
60 mV), it is, nonetheless, a major outward current in
human myocytes.16 Small changes of Ito during the early
phase of the AP can profoundly affect the activation of
other plateau currents, such as Ca2 and the delayed
outward K currents, influencing the AP duration and
Ca2 influx.27
In conclusion, prolongation of AP duration, induced by
clinically relevant concentrations of sevoflurane, appears
due to the suppression of Ito in rat ventricular myocytes.
Considering that the voltage and time dependence of Ito
in human ventricular myocytes are similar to those found
in rat heart cells16 and prolongation of AP duration in
failing human heart seems to be prominently caused by
a reduction in the level of Kv4.3 mRNA, resulting in
down-regulation of Ca2-independent Ito,
42 suppression
of Ito by sevoflurane may partly account for the clinical
observation of QTc prolongation in humans. In addition,
considering the presence of Iks in healthy human ventri-
cle,43,44 inhibition of Iks by sevoflurane
8 may also con-
tribute to QTc prolongation.
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